Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

NCT ID: NCT04956809

Last Updated: 2023-12-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-22
• Study Completion Date: 2023-06-01

Brief Summary

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

Conditions

HFrEF

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dapagliflozin 10mg

Active arm will be 6 weeks in duration, separated by a 2-week wash-out period.

Group Type: ACTIVE_COMPARATOR

Dapagliflozin 10Mg Tab

Intervention Type: DRUG

This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.

Placebo

Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.

Interventions

Dapagliflozin 10Mg Tab

This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.

Intervention Type: DRUG

Placebo

This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of HFrEF with NYHA Class II-III functional class, which has been present for at least two months

2. Left ventricular ejection fraction ≤ 40%

3. Stable medical therapy for at least 1 month

4. Plasma NT-proBNP level of: ≥ 200pg/mL; OR ≥ 125pg/mL if they were hospitalized for HF within the past 12 months; or ≥ 250 pg/mL if patient had atrial fibrillation/flutter on baseline ECG

Exclusion Criteria

1. Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or previous intolerance of an SGLT2 inhibitor

2. Type 1 diabetes mellitus

3. Age <18 years old

4. Pregnancy: Women of childbearing potential will undergo a urine pregnancy test during the screening visit.

5. Uncontrolled atrial fibrillation, as defined by a resting heart rate > 100 beats per minute at the time of the baseline assessment

6. Paroxysmal atrial fibrillation (Afib) or flutter with >1 hour of continuous Afib documented within the previous 6 months (prior to screening or randomization), direct-current (DC) cardioversion or ablation procedure for Afib within 6 months, or plan to attempt to restore sinus rhythm (with drug therapy, ablation, or DC cardioversion) within 6 months of randomization. Subjects with persistent Afib and no sinus rhythm documented in the prior 6 months are permitted.

7. Hemoglobin < 10 g/dL

8. eGFR < 25 mL/min/1.73m^2, or unstable or rapidly progressing renal disease at the time of randomization

9. Subject inability/unwillingness to exercise

10. Greater than moderate left sided valvular disease (mitral regurgitation, aortic stenosis, aortic regurgitation), moderate or greater mitral stenosis, severe right-sided valvular disease

11. Known hypertrophic, infiltrative, restrictive or inflammatory cardiomyopathy

12. Clinically significant pericardial disease, as per investigator judgment

13. Current angina due to clinically significant epicardial coronary disease, as per investigator judgment

14. Acute coronary syndrome or coronary intervention within the past 2 months

15. Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension)

16. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary Disease meeting Stage III or greater GOLD criteria (FEV1<50% predicted), treatment with oral steroids within the past 6 months for an exacerbation of obstructive lung disease, current use of supplemental oxygen aside from nocturnal oxygen for the treatment of obstructive sleep apnea.

• Desaturation to <90% on the baseline maximal effort cardiopulmonary exercise test will also be grounds for exclusion

17. Clinically-significant ischemia, as per investigator's judgement, on stress testing without either (1) subsequent revascularization, (2) an angiogram demonstrating the absence of clinically significant epicardial coronary artery disease, as per investigator judgment; (3) a follow-up 'negative' stress test, particularly when using a more specific technique (i.e., a negative perfusion imaging test following a 'positive' ECG stress test)

• Exercise induced regional wall motion abnormalities suggestive of ongoing ischemia during the baseline maximal effort cardiopulmonary exercise test will be exclusionary

18. Implantation of a CRT device within 12 weeks prior to enrollment or intent to implant a CRT device during the study period

19. Previous cardiac transplantation or implantation of a ventricular assist device, or implantation expected after randomization

20. Symptomatic bradycardia or second- or third-degree heart block, in the absence of a pacemaker

21. Significant liver disease impacting synthetic function or volume control (ALT/AST > 3x ULN, Albumin < 3.0 g/dL)

22. Severe right ventricular dysfunction

23. Baseline resting seated systolic blood pressure > 180 mmHg or <90 mmHg

24. Orthostatic blood pressure response to the transition from supine to standing (>20 mmHg reduction in systolic blood pressure 2-3 minutes after standing)

25. Active participation in another study that utilizes an investigational agent (observational studies/registries allowed)

26. Any condition that, in the opinion of the investigator, will interfere with the completion of the study. This may include comorbid or psychiatric conditions that may impede successful completion of the protocol, or logistical concerns (e.g. inability to travel to the exercise unit).

-

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Kenneth B Margulies

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

848538

Identifier Type: -

Identifier Source: org_study_id